集体诉讼指控DexCom和DXC Technology使用证券欺诈和虚报。 Class action lawsuits accuse DexCom and DXC Technology of securities fraud and misrepresentation.

针对德克斯康 (DXCM) 和德克斯科技公司 (DXC) 提起的集体诉讼指控证券欺诈和对正在进行的"转型之旅"和被收购公司的整合进行虚假陈述. Class action lawsuits filed against DexCom (DXCM) and DXC Technology Company (DXC) allege securities fraud and misrepresentation of ongoing "transformation journeys" and integration of acquired companies. DexCom的诉讼侧重于其第2,2024号问题收入中指称的虚假陈述,而DXC Technology的指控包括可能的递延费用削减和有限的融合努力。 DexCom's lawsuit focuses on alleged false statements in its Q2 2024 earnings, while DXC Technology's allegations include possible deferred cost reductions and limited integration efforts. 在规定期限内购买DXCM或DXC股份的股东可能有资格获得可能的回收。 Shareholders who purchased DXCM or DXC shares during the specified periods may be eligible for potential recovery.